XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Cash flows from operating activities:              
Net income (loss) $ (6,411) $ 5,793 $ 9,200 $ 4,507 $ (8,326) $ 23,142  
Adjustments to reconcile net income to net cash provided by operating activities:              
Depreciation and amortization         9,963 4,459  
Payment of interest expense on finance leases         (22) 0  
Non-cash operating lease cost         1,136 880  
Goodwill impairment 0   0   18,144 0 $ (0)
Change in fair value of contingent consideration 4,150   0   (16,176) 0  
Loss on disposal of fixed assets         287 927  
Loss on impairment of intangible asset         1,025 303 (389)
Stock-based compensation expense         3,953 4,140  
Deferred income taxes         (3,302) 941  
Provision (recovery) for doubtful accounts         (482) (450)  
Provision for inventory         4,205 1,062  
Amortization of acquisition-related inventory step-up         7,396 0  
Accretion of amortized cost of investments         3 (1,075)  
Changes in operating assets and liabilities:              
Accounts receivable         7,811 (2,751)  
Inventories         (8,840) (6,600)  
Prepaid expenses, other current and long-term assets         (989) 440  
Accounts payable         (1,904) (335)  
Operating lease liabilities         (1,286) (796)  
Accrued expenses, other current and long-term liabilities         (2,340) (681)  
Income taxes         222 377  
Net cash provided by operating activities         10,478 23,983  
Cash flows from investing activities:              
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired         (93,859) 0  
Proceeds from maturities of investments         27,000 87,594  
Purchases of investments         (20,035) (86,368)  
Purchases of property and equipment         (1,179) (2,559)  
Net cash used in investing activities         (88,073) (1,333)  
Cash flows from financing activities:              
Payments made on finance leases         (155) 0  
Repurchases of common stock         0 (30,000)  
Repayments of long term debt         (25,351) 0  
Proceeds from long term debt         50,000 0  
Cash paid for tax withheld on vested restricted stock awards         (224) (245)  
Proceeds from exercises of equity awards         68 21,825  
Net cash provided by (used in) financing activities         24,338 (8,420)  
Exchange rate impact on cash         10 109  
(Decrease)/Increase in cash and cash equivalents         (53,247) 14,339  
Cash and cash equivalents at beginning of period   $ 157,463   $ 89,042 157,463 89,042 89,042
Cash and cash equivalents at end of period 104,216   103,381   104,216 103,381 $ 157,463
Supplemental disclosure of cash flow information:              
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019 $ 603   $ 488   1,739 1,482  
Non-cash Investing Activities:              
Purchases of property and equipment included in accounts payable and accrued expenses         44 132  
Consideration for acquisitions included in accounts payable and accrued expenses         1,209 0  
Acquisition-related contingent consideration         69,076 0  
Accounting Standards Update 2016-02 [Member]              
Supplemental disclosure of cash flow information:              
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019         $ 0 $ 24,110